Adc Therapeutics SA

NYSE:ADCT   3:29:05 PM EDT
4.99
+0.27 (+5.72%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)383.79M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$57.55 Million
Adjusted EPS-$0.52
See more estimates
10-Day MA$4.70
50-Day MA$3.83
200-Day MA$6.41
See more pivots

Adc Therapeutics SA Stock, NYSE:ADCT

Biop??le, Route de la Corniche 3B, Epalinges, Vaud 1066
Switzerland
Phone: +41.212.653.02.00
Number of Employees: 312

Description

ADC Therapeutics SA is a clinical-stage biotechnology company. It engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.